Fig. 6.
![Fig. 6. Comparison of the immunotherapy achieved against BCL1 with anti-Id IgG and BsAb. / Groups of 5 huCD64+ age-matched mice received the treatment schedule shown in Figure 3. However, mice were inoculated with 105 BCL1 tumor cells intraperitoneally on day 0 and were treated with twice-daily doses of (a) 0.1, (b) 1, (c) 10, or (d) 100 μg mAb or BsAb intraperitoneally on days 1 to 5 (either 1, 10, 100, or 1000 μg in total/mouse). Treatment was as indicated: PBS (●), anti-Id IgG (▵), or [huCD64 × Id] BsAb (○). Symbols on plots show antibody specificity. Survival was recorded daily, and similar results were obtained in at least 3 similar experiments.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/96/10/10.1182_blood.v96.10.3544/5/h82200347006.jpeg?Expires=1735834912&Signature=fM09aQzxfz4iVQ944YPKz1YFEey9Kv2UZXbCANEhpnO88LY1-kwrk11rCSdorH-zs1mXhgxiIS2U9Cbr5CiBNikjxX1GbV8DKPStajt~xITMzzkh0WJSVzpm4UvVQFLuu-IdLSTvAwiB6s47Vf1kYn4qUFXUYwW6qqOq94qUrIBETxRZihMvv0K~cWGpRg8-PUymtxwIS5eneYOxbrXGDjLz7MN2L5k1WtqfeTmFlNm82qtWMo9AYjijwMxkrEBpxSd14qZT63GYK-IRMntv~0hNbMjqfaSG9k0nzGSuaXqSZQAqVR9q-WtL8A-OZd-y-e7l5KSlqqcNL8h~avdLpA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Comparison of the immunotherapy achieved against BCL1 with anti-Id IgG and BsAb.
Groups of 5 huCD64+ age-matched mice received the treatment schedule shown in Figure 3. However, mice were inoculated with 105 BCL1 tumor cells intraperitoneally on day 0 and were treated with twice-daily doses of (a) 0.1, (b) 1, (c) 10, or (d) 100 μg mAb or BsAb intraperitoneally on days 1 to 5 (either 1, 10, 100, or 1000 μg in total/mouse). Treatment was as indicated: PBS (●), anti-Id IgG (▵), or [huCD64 × Id] BsAb (○). Symbols on plots show antibody specificity. Survival was recorded daily, and similar results were obtained in at least 3 similar experiments.
